TCGA-AQ-A1H3-01A-31R-A13Q-07
— · A
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- A
- subtype
- A
- overall_survival_months
- 33
- os_event
- false
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- UV_RESPONSE_DN+0.450
- TGF_BETA_SIGNALING+0.420
- HEDGEHOG_SIGNALING+0.400
- TNFA_SIGNALING_VIA_NFKB+0.390
- PROTEIN_SECRETION+0.350
- KRAS_SIGNALING_UP+0.320
- APOPTOSIS+0.290
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.280
- INFLAMMATORY_RESPONSE+0.280
- IL6_JAK_STAT3_SIGNALING+0.270
Top 10 suppressed
- MYC_TARGETS_V2-0.500
- OXIDATIVE_PHOSPHORYLATION-0.420
- MTORC1_SIGNALING-0.290
- MYC_TARGETS_V1-0.270
- PANCREAS_BETA_CELLS-0.270
- GLYCOLYSIS-0.260
- UNFOLDED_PROTEIN_RESPONSE-0.230
- REACTIVE_OXYGEN_SPECIES_PATHWAY-0.220
- DNA_REPAIR-0.210
- E2F_TARGETS-0.210
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | TCGA-AR-A24O-01A-11R-A169-07 | — | A | 0.885 |
| 2 | TCGA-BH-A0DT-01A-21R-A12D-07 | — | A | 0.831 |
| 3 | TCGA-D8-A1JH-01A-11R-A13Q-07 | — | A | 0.830 |
| 4 | SRR5088836 | — | — | 0.827 |
| 5 | TCGA-86-6562-01A-11R-1755-07 | — | cohortA1 | 0.814 |
| 6 | TCGA-BH-A1EO-01A-11R-A137-07 | — | A | 0.811 |
| 7 | TCGA-CR-7376-01A-11R-2132-07 | — | — | 0.802 |
| 8 | TCGA-A1-A0SD-01A-11R-A115-07 | — | A | 0.801 |
| 9 | TCGA-EW-A1J2-01A-21R-A13Q-07 | — | A | 0.792 |
| 10 | TCGA-J2-8192-01A-11R-2241-07 | — | cohortA1 | 0.786 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 32 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| UV_RESPONSE_DN | 0.450 | Inavolisib | — uncovered |
| TGF_BETA_SIGNALING | 0.420 | Inavolisib | — uncovered |
| HEDGEHOG_SIGNALING | 0.400 | Inavolisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.390 | Inavolisib | — uncovered |
| PROTEIN_SECRETION | 0.350 | Remibrutinib | — uncovered |
| KRAS_SIGNALING_UP | 0.320 | Inavolisib | — uncovered |
| APOPTOSIS | 0.290 | Idelalisib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.280 | Inavolisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.280 | Idelalisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.270 | Inavolisib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.250 | Inavolisib | — uncovered |
| APICAL_SURFACE | 0.220 | Temsirolimus | — uncovered |
| MITOTIC_SPINDLE | 0.210 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.200 | Inavolisib | — uncovered |
| ANDROGEN_RESPONSE | 0.190 | Inavolisib | — uncovered |
| NOTCH_SIGNALING | 0.190 | Inavolisib | — uncovered |
| APICAL_JUNCTION | 0.180 | Inavolisib | — uncovered |
| ANGIOGENESIS | 0.160 | Remibrutinib | — uncovered |
| ADIPOGENESIS | 0.150 | Inavolisib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.150 | Remibrutinib | — uncovered |